Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL

Author:

Rousselot Philippe12ORCID,Coudé Marie Magdelaine34,Gokbuget Nicola5,Gambacorti Passerini Carlo6,Hayette Sandrine7,Cayuela Jean-Michel34,Huguet Françoise8,Leguay Thibaut9,Chevallier Patrice10,Salanoubat Celia11,Bonmati Caroline12,Alexis Magda13,Hunault Mathilde1415,Glaisner Sylvie16,Agape Philippe17,Berthou Christian18,Jourdan Eric19,Fernandes José20,Sutton Laurent21,Banos Anne22,Reman Oumedaly23,Lioure Bruno24,Thomas Xavier7,Ifrah Norbert1415,Lafage-Pochitaloff Marina25,Bornand Anne26,Morisset Laure27,Robin Valérie28,Pfeifer Heike29,Delannoy Andre30,Ribera Josep31,Bassan Renato32,Delord Marc33,Hoelzer Dieter34,Dombret Herve35,Ottmann Oliver G.36ORCID

Affiliation:

1. Hemato-Oncology Unit, Centre Hospitalier de Versailles, Le Chesnay, France;

2. Université Versailles Saint Quentin en Yvelines, EA4340, Université Paris-Saclay, Communauté Paris-Saclay, France;

3. Laboratory of Hematology, University Hospital Saint-Louis, Assistance Publique–Hôpitaux de Paris (AP-HP), Paris, France;

4. EA3518, University Paris Diderot, Paris, France;

5. Medicine Department II, Johann Wolfgang Goethe Universität, Frankfurt, Germany;

6. Department of Internal Medicine/Experimental Oncology, University of Milano Bicocca, Monza, Italy;

7. Division of Hematology, Hospices Civils de Lyon, INSERM U1052–Centre National de la Recherche Scientifique UMR 5286, Centre Hospitalier Lyon Sud, Pierre Bénite, France;

8. Division of Hematology, Institut Universitaire de Cancérologie, Toulouse, France;

9. Division of Hematology, Hôpital du Haut-Levêque, Pessac, France;

10. Hematology Department, CHU Hotel-Dieu, Nantes, France;

11. Division of Hematology, Centre Hospitalier Sud Francilien, Corbeil Essonne, France;

12. Division of Hematology, Hôpital de Brabois, Centre Hospitalier Universitaire de Nancy, Nancy, France;

13. Service d’Oncologie et d’Hématologie, Hôpital de la Source, Orléans, France;

14. Division of Hematology, Centre Hospitalier Universitaire d’Angers, Angers, France;

15. INSERM U892/Centre National de la Recherche Scientifique 6299, Angers, France;

16. Division of Hematology, Institut Curie–Hôpital Rene Huguenin, Saint-Cloud, France;

17. Division of Hematology, Centre Hospitalier Départemental Felix Guyon, Saint Denis, La Réunion, France;

18. Division of Hematology, Centre Hospitalier Universitaire de Brest, Brest, France;

19. Division of Hematology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France;

20. Division of Hematology, Hotel Dieu, Valenciennes, France;

21. Division of Hematology, Centre Hospitalier Victor Dupouy, Argenteuil, France;

22. Division of Hematology, Centre Hospitalier de la Côte Basque, Bayonne, France;

23. Division of Hematology, Centre Hospitalier Universitaire, Caen, France;

24. Division of Hematology, Hôpital de Hautepierre, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France;

25. Laboratoire de Cytogénétique Onco-Hématologique, CHU Timone Enfants, Aix-Marseille University, Marseille, France;

26. Service de Gériatrie Aigue Polyvalente and

27. Délégation à la Recherche Clinique et à l’Innovation, Hôpital Mignot, Le Chesnay, France;

28. Division of Hematology, CHR Mons-Hainaut, Mons, Belgium;

29. Department of Molecular Biology, Johann Wolfgang Goethe University, Frankfurt, Germany;

30. Département d’Hématologie, d’Oncologie Médicale et de Radiothérapie Oncologique, Centre Hospitalier de Jolimont-Lobbes, Haine Saint Paul, Belgium;

31. Department of Clinical Hematology, ICO-Hospital Germans Trias i Pujol, Jose Carreras Research Institute, Badalona, Spain;

32. Azienda ULSS 12 “Veneziana” Direttore U.O.C. Ematologia, Venezia, Italy;

33. Institut Universitaire d’Hématologie, Hôpital Saint-Louis, Paris, France;

34. Department of Hematology, Johann Wolfgang Goethe University, Frankfurt, Germany;

35. Division of Hematology, Hôpital Saint-Louis, AP-HP, University Paris Diderot, Paris, France; and

36. Institute of Cancer & Genetics, Cardiff University School of Medicine, Cardiff, United Kingdom

Abstract

Key Points Dasatinib, combined with low-intensity chemotherapy, gave 36% 5-year overall survival in Ph+ ALL patients older than age 55 years. Prospective monitoring of mutations may be useful to personalize therapy in Ph+ ALL patients not eligible for intensive therapies.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3